TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2139338
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (1 mg sub-lingually)
Study: 28221062
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
Study: 21752262
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 80 ppm
Study: 19770281
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with S/pre‐S1/pre‐S2 vaccine and lamivudine
Study: 19770281
Drug: Vaccine monotherapy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine monotherapy
Study: 15578399
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg po b.i.d. for 30 days
Study: 15578399
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg po b.i.d. for 45 days
Study: 15578399
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment for 45 days
Study: 8044602
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 1 g three times daily
Study: 2117858
Drug: Metrifonate (MT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (MT, 10 mg/kg body weight)
Study: 2117858
Drug: Praziquantel (PR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (PR, 40 mg/kg body weight)
Study: 31273511
Drug: HAI raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI raltitrexed (3 mg/m2 over 1 h) followed by oxaliplatin (130 mg/m2 over 2 h) every 3 weeks
Study: 21047395
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 to 20 mg/day) for 24 to 28 weeks
Study: 16202527
Drug: Bupivacaine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5 ml of 0.5% per trigger point)
Study: 8955972
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms.kg-1 and dexamethasone 4 mg (Group D)
Study: 6280600
Drug: Cefotaxime (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1-g dose)
Study: 28186251
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Normalized name: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 150 mg-150 mg-200 mg-300 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (single-tablet regimen)
Study: 25658240
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (129 mg flavonoids)
Study: 25799800
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (Mometasone furoate 0.1% cream) and Topical placental extract gel
Study: 25799800
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (Mometasone furoate 0.1% cream) and Topical Tacrolimus 0.1% cream
Study: 22736463
Drug: Supersaturated calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supersaturated calcium phosphate rinse (SCPR) four times daily
Study: 22736463
Drug: Customary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary care (topical mouth solutions made with salvia leaf extract, iodine-povidine, and fluconazole)
Study: 17006401
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (LD-OC) pill
Study: 11112975
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) users
Study: 9207371
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (100-200 mg once daily for 3-8 weeks)
Study: 9207371
Drug: Fluconazole tablets
Normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole tablets (100-200 mg once daily for 3-8 weeks)
Study: 2950303
Drug: Intramuscular vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccine (20 micrograms)
Study: 2950303
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (2 micrograms)
Study: 28476039
Drug: Nano-pulse stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-pulse stimulation (NPS) treatment
Study: 28476039
Drug: Control (surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (surgery or no treatment)
Study: 12514443
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner treatment with azithromycin (dose not specified)
Study: 1847363
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of intraarterial hepatic 5-fluorodeoxyuridine (FdUrd) as a radiosensitizer
Study: 26863234
Drug: l-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-citrulline
Study: 26863234
Drug: WBVT+l-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBVT+l-citrulline
Study: 22828696
Drug: Thoracic interlaminar
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic interlaminar epidural injections with or without steroids
Study: 20429696
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (reference group)
Study: 16153514
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation in patients with atrial fibrillation and echocardiographic risk factors
Study: 10549964
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg intramuscular pethidine
Study: 10549964
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg intramuscular diamorphine
Study: 10549964
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intramuscular pethidine
Study: 1750603
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscular diamorphine
Study: 367136
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of isosorbide dinitrate
Study: 30381248
Drug: Lisdexamfetamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine (100 mg)
Study: 30381248
Drug: d-Amphetamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (40 mg)
Study: 26888874
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of parenteral nutrition (n = 59)
Study: 26888874
Drug: Peripheral IV
Normalized name: Soluline 7-Day Peripheral IV Line Supply
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral IV administration of parenteral nutrition (n = 61)
Study: 25462646
Drug: Multi-family group
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-family group therapy (MFGT) intervention (six sessions)
Study: 24671340
Drug: nalmefene 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalmefene 18 mg/day
Study: 16203059
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pneumococcal conjugate vaccine (PCV)
Study: 12771523
Drug: Intravesical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical treatment with interferon‐a2b (IFN‐a2b); administered weekly for 2 months, then twice a month for 4 months, and monthly for 6 months.
Study: 12771523
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further treatment); 10 patients.
Study: 11879269
Drug: Group psychosocial
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychosocial intervention (six weekly cognitive/behavioral meetings)
Study: 9146780
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg three times daily
Study: 11904788
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg three times daily
Study: 339448
Drug: Twice-weekly continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly continuation regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Study: 339448
Drug: Twice-weekly continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly continuation regimen of streptomycin plus isoniazid after 6 weeks of initial daily triple chemotherapy
Study: 339448
Drug: Once-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly regimen of streptomycin plus isoniazid after 13 weeks of initial daily triple chemotherapy
Study: 339448
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of chemotherapy
Study: 339448
Drug: 18 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18 months of chemotherapy
Study: 20640848
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel (APG) applied after prosthesis implantation
Study: 19813467
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clarithromycin suspension (500 mg)
Study: 19813467
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clarithromycin suspension (500 mg)
Study: 17541852
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment in females with poor metabolic status (PM)
Study: 17541852
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment in males with poor metabolic status (PM)
Study: 17541852
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment in females with extensive metabolic status (EM)
Study: 17541852
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment in males with extensive metabolic status (EM)
Study: 12786918
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (9 mg/kg per day by mouth divided 3 times a day with food)
Study: 10925968
Drug: Celecoxib 25-400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 25-400 mg b.i.d.
Study: 10925968
Drug: Nonspecific NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonspecific NSAIDs (naproxen 500 mg b.i.d., diclofenac 50 or 75 mg b.i.d., ibuprofen 800 mg t.i.d.)
Study: 10925968
Drug: Celecoxib 100-400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100-400 mg b.i.d. (long-term open-label trial)
Study: 1346505
Drug: Zidovudine 400
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 400 mg daily
Study: 1346505
Drug: Zidovudine 800
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 800 mg daily
Study: 1346505
Drug: Zidovudine 1200
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1200 mg daily
Study: 1346505
Drug: Zidovudine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (all doses)
Study: 6593147
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride gel (5 min once weekly)
Study: 6593147
Drug: Fluoride-free dentifrice
Normalized name: potassium nitrate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride-free dentifrice (twice daily)
Study: 31570028
Drug: Dilapan-S with
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilapan-S with 200 mg oral mifepristone (study group)
Study: 30728457
Drug: Azacitidine (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (given prior to therapy with idarubicin and etoposide)
Study: 30728457
Drug: Azacitidine (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (given after therapy with idarubicin and etoposide)
Study: 25313094
Drug: Inosine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine 3 g/day
Study: 17110281
Drug: TCH346 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH346 0.5 mg
Study: 17110281
Drug: TCH346 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH346 2.5 mg
Study: 17110281
Drug: TCH346 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH346 10 mg
Study: 17110281
Drug: TCH346 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH346 (all doses)
Study: 2871667
Drug: Celiprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (100 mg oral dose, given 6 hours after symptom onset)
Study: 31644731
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for caregivers
Study: 23739574
Drug: DEX (0.5‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (0.5‐1.0 μg/kg load, 0.2‐0.6 μg×kg⁻¹×h⁻¹ for 24 hours)
Study: 23739574
Drug: Propofol (0.5‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5‐2.0 mg/kg load, 1‐3 mg×kg⁻¹×h⁻¹ for 72 hours)
Study: 23739574
Drug: Pethidine and
Normalized name: pethidine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine and other temporary medication (group C)
Study: 22051828
Drug: Linfonex™ 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linfonex™ 1000 mg
Study: 22051828
Drug: Cellcept™ 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellcept™ 1000 mg
Study: 16874422
Drug: Nickel sulphate
Normalized name: Nickel sulphate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulphate patch test
Study: 16874422
Drug: Negative fragrance
Normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative fragrance patch test
Study: 8094349
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg every 8 h for 7 days)
Study: 3322097
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg.kg‐1, 0.25 mg.kg‐1, 0.30 mg.kg‐1, 0.35 mg.kg‐1, 0.40 mg.kg‐1 (open study)
Study: 3322097
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg.kg‐1 (double-blind study)
Study: 29775954
Drug: Target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target group with specific physical therapy techniques added to conventional protocol
Study: 29775954
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with conventional physical therapy protocol
Study: 29363217
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo tolterodine 1 mg
Study: 25661312
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (further intravenous morphine only)
Study: 23301896
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ginseng twice daily for 3 months
Study: 21129375
Drug: Peginterferon (half-dose)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon (half-dose)
Study: 18351194
Drug: Patient-directed intervention
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-directed intervention (in subgroup with no aspirin use at baseline)
Study: 18351194
Drug: Reminder-only (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminder-only (in subgroup with no aspirin use at baseline)
Study: 39585
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol and 100 mg metoprolol
Study: 18316395
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily alcohol consumption (16.4‐42.6 g ethanol/day)
Study: 18316395
Drug: Moderate or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate or heavy alcohol drinkers (>or=42.7 g ethanol/day)
Study: 16602254
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment at 2.4 atm abs pressure with 90 minutes of 100% oxygen breathing
Study: 12963554
Drug: Gastric acid-lowering
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric acid-lowering medications (histamine receptor H2 antagonists or proton pump inhibitors)
Study: 12963554
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving gastric acid-lowering medications)
Study: 3494005
Drug: Doses to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses to the prostate in excess of 7000 cGy
Study: 3494005
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose to the regional lymphatics (4400 to 5100 cGy)
Study: 22499965
Drug: Oral Impact
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Impact for 5 days before surgery
Study: 20045497
Drug: Statin (simvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (simvastatin, moderate to high dose)
Study: 17901413
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter for 12 months
Study: 15486003
Drug: Remifentanil, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil, 1 microg kg(‐1) injected over 60 s, followed by infusion of 0.25 microg kg(‐1) min(‐1) for 10 min then 0.5 microg kg(‐1) min(‐1) for 10 min
Study: 12202963
Drug: High-dose clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clonidine (2.5 mg/kg)
Study: 10489843
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (100 microg or 200 microg daily)
Study: 1728438
Drug: Ro 42-5892
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42-5892 (600 mg p.o.)
Study: 6731326
Drug: Metoprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta 1-selective blocker), administered intravenously followed by oral treatment for 3 months.
Study: 15987349
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10; n = 79)
Study: 15987349
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30; n = 87)
Study: 15987349
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10)
Study: 15987349
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30)
Study: 8768856
Drug: MK-386 (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-386 (10-100 mg)
Study: 8768856
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg) + MK-386 (25 mg)
Study: 1725915
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg once daily, then 25 mg once daily, and finally 25 mg twice daily)
Study: 1725915
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg once daily, then 240 mg once daily, and finally 240 mg twice daily)
Study: 1725915
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg once daily and twice daily)
Study: 6789593
Drug: Thyrotrophin releasing
Normalized name: Thyrotrophin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin releasing hormone (TRH)
Study: 30612463
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine for 8 weeks
Study: 24433285
Drug: Febuxostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (10 mg/day for weeks 1-4, 20 mg/day for weeks 5-8, 40 mg/day from week 9 to week 108)
Study: 15589377
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 500 mg/day
Study: 15589377
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 1000 mg/day
Study: 2536288
Drug: Chemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy maintenance with MACC regimen (38 subjects)
Study: 2536288
Drug: Chemotherapy discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy discontinuation (36 subjects)
Study: 23342337
Drug: Implant-retained overdenture
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained overdenture (IOD) group
Study: 6370030
Drug: Chlorprothixene 1
Normalized name: chlorprothixene 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene 1 mg/kg i.m.